Belgian particle accelerator technology firm, IBA, announced on 13th June, 2023, that it has signed an equipment contract with one of its partners, CGN Medical Technology (CGNMT), for its Proteus®PLUS proton therapy system. The system, with one gantry treatment room, is to be installed in the West China International Cancer Treatment Center in Chengdu, Sichuan Province.
This is the second order from CGN Medical Technology for IBA&https://adarima.org/?aHR0cHM6Ly9tY3J5cHRvLmNsdWIvY2F0ZWdvcnJ5Lz93cHNhZmVsaW5rPVk1OEtmaHQzWlN3QXBic0NhZGZFZUZsZ2lIbmlrUlM5RFZHNUhhV2xVUVRFM1NrNUtOMmxvWVZSeVp6MDk-8217;s Proteus®PLUS system. Since the beginning of their successful collaboration, IBA has provided the key components of the Proteus®PLUS system to CGNMT, which will be installed at the hospital site. CGNMT will also be responsible for the installation, commissioning, service and maintenance of the proton therapy equipment.
With nine Proteus®PLUS systems installed in China since the beginning of its operations in the country, IBA has shown itself as a trusted and reliable partner in the Chinese market. IBA CEO, Olivier Legrain, has said he is impressed with the progress of their partner and looks forward to continuing the relationship with them to ensure the future success and expansion of proton therapy in the Chinese market.
Chairman of CGN Nuclear Technology Development, HU Dongming, expressed his pleasure in working with West China International Cancer Treatment Center and its potential in strengthening the relationship with IBA. He also thanked the IBA management team for visiting the CGN office in Shenzhen and celebrating the fantastic progress made in the delivery of innovative technology to the Chinese market.
IBA is the world leader in particle accelerator technology and the leading supplier of equipment and services in the field of proton therapy, widely recognized as the most advanced form of radiation therapy available today. The company is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp), meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information about the company is available on its website: www.iba-worldwide.com.
CGNNT (stock code: 000881.SZ) is a leading company in the nuclear technology application industry that was restructured and listed on the Shenzhen Stock Exchange in February 2017. The company has completed the layout of core business units such as accelerator manufacturing, application development and technical service, and modified polymer material, leading to its market share leading the nation.
CGNNT mainly incubates emerging services such as radiation detection and security inspection and new irradiation applications while also actively expanding to high-end fields such as nuclear medicine (especially PT field), nuclear agricultural science, and nuclear environmental protection, with the market size firmly ahead in China.
More information about CGNNT is available at http://www.cgnnt.com.cn.
Inquiries and requests for further information may be directed to Soumya Chandramouli, Chief Financial Officer, at +32 10 475 890 or [email protected]. Alternatively, Olivier Lechien, Corporate Communication Director, may be contacted at +32 10 475 890 or [email protected]. Consilium Strategic Communications representatives, Amber Fennell, Matthew Neal, and Lucy Featherstone, are also available at +44 (0) 20 3709 5700 or [email protected].
The contract announcement was made on the IBA website and accompanied by an image of the IBA logo.